Life Saving Drugs
We engage in distribution and supply of a wide range of Life Saving Drugs.All the drugs are directly sourced from Manufacturer, hence no chance of Counterfeit Drugs. All these products are offered with multiple company choice with variable price range.Our range includes cardio- Diabetic drugs,Anti Snake Venom, AGGS and other Life Saving Drugs. We deal in companies like Boehringer Ingelheim, Abbott, Novartis, Nicholas piramal etc.
Pentaglobin 250 Mg Injection
Approx. Rs 5,172 / BottleGet Latest Price
Product Details:| Brand | Biotest |
| Usage/Application | Clinical |
| Composition | Pentaglobin |
| Injectable Form | Liquid |
| Dose | 250 mg |
| Packaging Size | 10 ml |
| Medicine Type | Injection |
| Product Type | Finished Product |
| Gender | Unisex |
We offer Pentaglobin 250 Mg Injection to our clients.
Active ingredient:
- Human immunoglobulin for intravenous administration Store protected from light at +2 Degree C to 8 Degree C Keep out of reach of children I Approved by th german health authorities
Additional Information:
Mozifor 1.2ml ( Plexrixafor) Injection
Approx. Rs 23,700 / PackGet Latest Price
Product Details:| Minimum Order Quantity | 1 Pack |
| Brand | Hetero |
| Usage/Application | Personal |
| Composition | Plexrixafor |
| Injectable Form | Liquid |
| Dose | 1.2ml |
| Packaging Size | Vial |
| Medicine Type | Injection |
| Product Type | Finished Product |
| Gender | Unisex |
| Packaging Type | Box |
| Power | 1.2Ml Injection |
| Shelf Life | 25 Months |
Mozobil (plerixafor) injection is a sterile, preservative-free, clear, colorless to pale-yellow, isotonic solution for subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor. Each single-use vial is filled to deliver 1.2 mL of the sterile solution that contains 24 mg of plerixafor and 5.9 mg of sodium chloride in Water for Injection adjusted to a pH of 6.0 to 7.5 with hydrochloric acid and with sodium hydroxide, if required.
Plerixafor is a hematopoietic stem cell mobilizer with a chemical name l, 1’-[1,4phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane. It has the molecular formula C28H54N8. The molecular weight of plerixafor is 502.79 g/mol.
Mozobil®(plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored.
Begin treatment with Mozobil after the patient has received G-CSF once daily for four days [see Recommended Concomitant Medications]. Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.
The recommended dose of Mozobil by subcutaneous injection is based on body weight:
- 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg. [see CLINICAL PHARMACOLOGY]
- 0.24 mg/kg of body weight for patients weighing >83 kg.
Use the patient’s actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation:
0.012 × patient’s actual body weight (in kg) = volume to be administered (in mL)
In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
Based on increasing exposure with increasing body weight, the Mozobil dose should not exceed 40 mg/day.
Additional Information:
Factor Eight Injection
Approx. Rs 3,700 / UnitGet Latest Price
Product Details:| Minimum Order Quantity | 1 Unit |
| Brand | Baxter |
| Usage/Application | Clinical |
| Composition | Plasma and Serum Glycoprotein involved in blood coagulation |
| Injectable Form | Lyophilized Powder |
| Medicine Type | Allopathic |
| Form Of Medicine | Injectable |
Factor 8 is indicated for replacement therapy in patients with von Willebrand's disease in whom factor VIII activity is reduced. Replacement therapy with Factor to control haemorrhages and to prevent bleeding episodes associated with surgical interventions follows the guidelines given for haemophilia A.
Human coagulation factor VIII is a preparation of plasma protein fraction that contains the glycoprotein coagulation factor VIII (plasma and serum glycoprotein involved in blood coagulation) together with varying amounts of Willebrand factor, depending on the method of preparation
Foreign Names- Factor VIII coagulationis sanguinis humanus (Latin)
- Blutgerinnungsfaktor VIII vom Menschen (German)
- Facteur VIII de coagulation sanguine humain (French)
- Factor VIII de coagulacion sanguinea humana (Spanish)
Cafirate Injection
Product Price :Get Latest Price
Product Details:| Usage | Clinical and Hospital |
| Packaging Type | Glass Bottle |
| Medicine Type | Allopathic |
| Composition | Caffeine Citrate Injection USP |
| Dose | 20 mg/3 ml |
We offer Cafirate Injection to our clients.
Other Details:
- For IV use only
Additional Information:
Pradaxa Capsules
Product Price :Get Latest Price
Product Details:| Manufacturer | BOHRINGER INGHELIUM |
| Treatment | FOR DIABETICS |
| Prescription/Non prescription | Prescription |
| Product Type | Finished Product |
| Usage | Hospital, Personal, Clinical |
| Packaging Size | 6 x 10 Capsules |
| Form | Tablet |
| Composition | Dabigatran Etexilate mesilate |
| Available Dose | 110,150 mg |
We offer Pradaxa Capsules to our clients.
Additional Information:
Explore More Products
Jimit Bhinde (Marketing Manager)
Mumbai - 420031, Maharashtra, India
© D. Vijay Pharma Private Limited. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited
